Mononuclear Pd(II) and Pt(II) complexes with an α-N-heterocyclic thiosemicarbazone: cytotoxicity, solution behaviour and interaction versus proven models from biological media

被引：43

作者：

Matesanz, Ana I. ^{[1
,2
]}

Jimenez-Faraco, Eva ^{[1
,2
]}

Ruiz, Maria C. ^{[3
]}

Balsa, Lucia M. ^{[3
]}

Navarro-Ranninger, Carmen ^{[1
,2
]}

Leon, Ignacio E. ^{[3
]}

Quiroga, Adoracion G. ^{[1
,2
]}

机构：

[1] Univ Autonoma Madrid, Dept Quim Inorgan, Madrid 28045, Spain

[2] Univ Autonoma Madrid, IAdChem Inst Adv Res Chem Sci, Madrid 28045, Spain

[3] Univ Nacl La Plata, Ctr Quim Inorgan, CEQUINOR, CONICET,Fac Ciencias Exactas, RA-1900 La Plata, Buenos Aires, Argentina

来源：

INORGANIC CHEMISTRY FRONTIERS | 2018年 / 5卷 / 01期

关键词：

ALPHA-(N)-HETEROCYCLIC CARBOXALDEHYDE THIOSEMICARBAZONES; RIBONUCLEOTIDE REDUCTASE; ANTIPROLIFERATIVE ACTIVITY; VANADYL(IV) COMPLEX; INDIVIDUAL CELLS; DNA INTERACTIONS; TUMOR-CELLS; COMET ASSAY; ANTICANCER; PALLADIUM;

D O I：

10.1039/c7qi00446j

中图分类号：

O61 [无机化学];

学科分类号：

070301 ; 081704 ;

摘要：

Two Pd(II) and Pt(II) complexes with two pyrrol-2-carbaldehyde N-p-chlorophenylthiosemicarbazone ligands are designed and characterized showing mononuclear structures. An important pharmacological property for both compounds is the high selectivity for tumor cells and a lack of activity in healthy cells. The Pd(II) compound shows a higher antitumor activity and selectivity than the Pt(II) compound. Both complexes present a variety of biological interactions: with DNA models (pBR322 and CT DNA), proteins (lysozyme and RNase) and other biological targets like proteosome. Our results show that the Pd(II) complex is a more interesting candidate for potential anticancer therapies than the Pt(II) complex, and we provide new insight into the design and synthesis of palladium compounds as potential antitumor agents.

引用

页码：73 / 83

页数：11

共 53 条

[1]

Adams J, 1999, CANCER RES, V59, P2615

[2] SOME HETEROCYCLIC THIOSEMICARBAZONES [J].

ANDERSON, FE ;

DUCA, CJ ;

SCUDI, JV .

JOURNAL OF THE AMERICAN CHEMICAL SOCIETY, 1951, 73 (10) :4967-4968

[3]

[Anonymous], DRUG DNA INTERACTION

[4]

[Anonymous], 1997, SHELTXTL NTVERSION 6

[5] INHIBITION OF TUMOR-CELL TRANSPLANTABILITY BY IRON AND COPPER-COMPLEXES OF 5-SUBSTITUTED 2-FORMYLPYRIDINE THIOSEMICARBAZONES [J].

ANTHOLINE, WE ;

KNIGHT, JM ;

PETERING, DH .

JOURNAL OF MEDICINAL CHEMISTRY, 1976, 19 (02) :339-341

[6] HUMAN INTERFERON - MASS-PRODUCTION IN A NEWLY ESTABLISHED CELL LINE, MG-63 [J].

BILLIAU, A ;

EDY, VG ;

HEREMANS, H ;

VANDAMME, J ;

DESMYTER, J ;

GEORGIADES, JA ;

DESOMER, P .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1977, 12 (01) :11-15

[7] Interactions of anticancer Pt compounds with proteins: an overlooked topic in medicinal inorganic chemistry? [J].

Casini, Angela ;

Reedijk, Jan .

CHEMICAL SCIENCE, 2012, 3 (11) :3135-3144

[8] BINDING OF CIS-DICHLORODIAMMINEPLATINUM(II) AND TRANS-DICHLORODIAMMINEPLATINUM(II) TO DNA - EVIDENCE FOR UNWINDING AND SHORTENING OF THE DOUBLE HELIX [J].

COHEN, GL ;

BAUER, WR ;

BARTON, JK ;

LIPPARD, SJ .

SCIENCE, 1979, 203 (4384) :1014-1016

[9] The comet assay: What can it really tell us? [J].

Collins, AR ;

Dobson, VL ;

Dusinska, M ;

Kennedy, G ;

Stetina, R .

MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS, 1997, 375 (02) :183-193

[10] The anticancer drug Dp44mT inhibits T-cell activation and CD25 through a copper-dependent mechanism [J].

Gundelach, Justin H. ;

Madhavan, Ajay A. ;

Wettstein, Peter J. ;

Bram, Richard J. .

FASEB JOURNAL, 2013, 27 (02) :782-792

← 1 2 3 4 5 6 →